Eli Lilly completes $38/share acquisition of Centessa, taking company private

Filed June 24, 2026 · Period ending June 24, 2026 · ~1 min read

Key Changes

• high

  Eli Lilly acquired all outstanding shares for $38 cash plus contingent value rights worth up to $9/share tied to unspecified milestones, totaling up to $47/share. Centessa is now a wholly owned Lilly subsidiary.

  Item 2.01 — Completion of Acquisition or Disposition of Assets verify on EDGAR →
• high

  Centessa delisted from Nasdaq effective June 23, 2026, and will suspend SEC reporting obligations. Shareholders lost all rights except the right to receive transaction consideration.

  Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule verify on EDGAR →
• high

  CEO Mario Alberto Accardi and three other executive officers departed at closing. Eight directors resigned and were replaced by two Lilly appointees: Christopher Stokes and Kristina Mignon Wright.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →